Aug 22 (Reuters) - Sophiris Bio Inc :
* Currently evaluating options to further advance clinical development of topsalysin - sec filing
* "will require significant additional funding to advance topsalysin in clinical development"
* Could use dilutive funding options like equity financing or "non-dilutive" funding options to fund future clinical development of topsalysin
* Do not plan on pursuing new clinical trials, including a second phase 3 trial in bph, unless we obtain additional financing
* Believe that earliest we could commercialize topsalysin for treatment of localized prostate cancer would be in late 2021 or into 2022 Source text (bit.ly/2bHNTCN) Further company coverage: